{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:48:50Z","timestamp":1788241730826,"version":"build-2803163510"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,24]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The purpose of this review is to summarize the current evidence for valbenazine and deutetrabenazine use for the treatment of tardive dyskinesia (TD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>A literature search was conducted to gather relevant data regarding the use of valbenazine and deutetrabenazine for TD management. PubMed, MEDLINE, and ClinicalTrials.gov were searched using the following keywords and MeSH terms: valbenazine, deutetrabenazine, tardive dyskinesia, VMAT2 inhibitors, and vesicular monoamine transporter 2 inhibitors. Randomized, double-blind, placebo-controlled trials and meta-analyses published in English from April 2015 to August 2019 were included. Valbenazine 40\u201380 mg and deutetrabenazine 12\u201336 mg per day have been evaluated for the treatment of TD. Abnormal Involuntary Movement Scale (AIMS) scores decline similarly (by 2\u20135 points) with use of either agent. AIMS response rates, defined by a 50% decline in symptoms, range from 33% to 50%. Both agents are well tolerated, with somnolence and akathisia reported most frequently (at low rates). Agent selection may be guided by manufacturer labeling recommendations for special populations and cost considerations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Valbenazine and deutetrabenazine were demonstrated to be effective in decreasing AIMS scores and were well tolerated in randomized controlled trials. These treatments may be considered as a next-line option when traditional strategies are not feasible or are ineffective. Head-to-head studies are warranted to decipher if either agent is preferable in terms of efficacy or tolerability.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ajhp\/zxz299","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T09:06:45Z","timestamp":1579856805000},"page":"167-174","source":"Crossref","is-referenced-by-count":14,"title":["Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia"],"prefix":"10.1093","volume":"77","author":[{"given":"Farah","family":"Khorassani","sequence":"first","affiliation":[{"name":"Department of Clinical Health Professions, St. John\u2019s University College of Pharmacy and Health Sciences, Queens, NY"},{"name":"Department of Pharmacy, Bellevue Hospital Center, St. John\u2019s University College of Pharmacy and Health Sciences, Queens, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiranjit","family":"Luther","sequence":"additional","affiliation":[{"name":"St. John\u2019s University College of Pharmacy and Health Sciences, Queens, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Om","family":"Talreja","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Allegheny General Hospital, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,24]]},"reference":[{"key":"2020012404063936100_CIT0001","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0447.1964.tb05731.x","article-title":"Neurological symptoms in pharmacotherapy of psychoses","volume":"40","author":"Faurbye","year":"1964","journal-title":"Acta Psychiatr Scand"},{"key":"2020012404063936100_CIT0002","volume-title":"5th edition. Arlington, VA","author":"Diagnostic and statistical manual of mental disorders","year":"2013"},{"key":"2020012404063936100_CIT0003","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/wps.20579","article-title":"Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis","volume":"17","author":"Carbon","year":"2018","journal-title":"World Psychiatry."},{"key":"2020012404063936100_CIT0004","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis","volume":"78","author":"Carbon","year":"2017","journal-title":"J Clin Psychiatry."},{"key":"2020012404063936100_CIT0005","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1503\/cmaj.1041064","article-title":"Modern antipsychotic drugs: a critical overview","volume":"172","author":"Gardner","year":"2005","journal-title":"CMAJ."},{"key":"2020012404063936100_CIT0006","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/070674370505000907","article-title":"Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction","volume":"50","author":"Margolese","year":"2005","journal-title":"Can J Psychiatry"},{"key":"2020012404063936100_CIT0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2018.02.012","article-title":"Clinical risk factors for the development of tardive dyskinesia","volume":"389","author":"Solmi","year":"2018","journal-title":"J Neurol Sci."},{"key":"2020012404063936100_CIT0008","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"2020012404063936100_CIT0009","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes","volume":"81","author":"Bhidayasiri","year":"2013","journal-title":"Neurology."},{"key":"2020012404063936100_CIT0010","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17r11852","article-title":"Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia","volume":"79","author":"Mentzel","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"2020012404063936100_CIT0011","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"81","author":"Bhidayasiri","year":"2013","journal-title":"Neurology."},{"key":"2020012404063936100_CIT0012","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2018.02.010","article-title":"Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm","volume":"389","author":"Bhidayasiri","year":"2018","journal-title":"J Neurol Sci."},{"key":"2020012404063936100_CIT0013","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1345\/aph.1P312","article-title":"Tetrabenazine for the treatment of tardive dyskinesia","volume":"45","author":"Leung","year":"2011","journal-title":"Ann Pharmacother"},{"key":"2020012404063936100_CIT0014","volume-title":"Xenazine (tetrabenazine) package insert","year":"2017"},{"key":"2020012404063936100_CIT0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5334\/tohm.129","article-title":"Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington\u2019s and other diseases","volume":"22","author":"Shen","year":"2013","journal-title":"Tremor Other Hyperkinetic Mov (N Y)"},{"key":"2020012404063936100_CIT0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852917000621","article-title":"Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less \u201cgo\u201d and more \u201cstop\u201d from the motor striatum for robust therapeutic effects","volume":"23","author":"Stahl","year":"2018","journal-title":"CNS Spectr"},{"key":"2020012404063936100_CIT0017","volume-title":"Austedo (deutetrabenazine) package insert","year":"2019"},{"key":"2020012404063936100_CIT0018","volume-title":"Ingrezza (valbenazine) package insert","year":"2019"},{"key":"2020012404063936100_CIT0019","author":"U.S. National Library of Medicine"},{"key":"2020012404063936100_CIT0020","doi-asserted-by":"crossref","first-page":"S27.007","DOI":"10.1212\/WNL.86.16_supplement.S27.007","article-title":"A phase 2 study of valbenazine (NBI-98854) for treatment of tardive dyskinesia: KINECT 2 (S27.007)","volume":"86","author":"Factor","year":"2016","journal-title":"Neurology."},{"key":"2020012404063936100_CIT0021","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","journal-title":"Am J Psychiatry."},{"key":"2020012404063936100_CIT0022","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.4088\/JCP.17m11777","article-title":"The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study","volume":"78","author":"Factor","year":"2017","journal-title":"J Clin Psychiatry."},{"key":"2020012404063936100_CIT0023","author":"U.S. National Library of Medicine"},{"key":"2020012404063936100_CIT0024","author":"U.S. National Library of Medicine"},{"key":"2020012404063936100_CIT0025","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study","volume":"88","author":"Fernandez","year":"2017","journal-title":"Neurology."},{"key":"2020012404063936100_CIT0026","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiatry."},{"key":"2020012404063936100_CIT0027","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-319918","article-title":"Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia","author":"Fernandez","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2020012404063936100_CIT0028","author":"U.S. National Library of Medicine"},{"key":"2020012404063936100_CIT0029","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.1972.01750250081011","article-title":"Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine","volume":"27","author":"Kazamatsuri","year":"1972","journal-title":"Arch Gen Psychiatry"},{"key":"2020012404063936100_CIT0030","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1176\/ajp.130.4.479","article-title":"Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine","volume":"130","author":"Kazamatsuri","year":"1973","journal-title":"Am J Psychiatry."},{"key":"2020012404063936100_CIT0031","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1176\/ajp.156.8.1279","article-title":"Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol","volume":"156","author":"Ondo","year":"1999","journal-title":"Am J Psychiatry."},{"key":"2020012404063936100_CIT0032","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2018.02.010","article-title":"Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm","volume":"389","author":"Bhidayasiri","year":"2018","journal-title":"J Neurol Sci."},{"key":"2020012404063936100_CIT0033","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2147\/DDDT.S133205","article-title":"Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Solmi","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"2020012404063936100_CIT0034","article-title":"Lexi-drugs"},{"key":"2020012404063936100_CIT0035","article-title":"Lexi-drugs"},{"key":"2020012404063936100_CIT0036","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/01.pra.0000367776.96012.ca","article-title":"Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines","volume":"16","author":"Velligan","year":"2010","journal-title":"J Psychiatr Pract."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/3\/167\/31953308\/zxz299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/3\/167\/31953308\/zxz299.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T17:13:24Z","timestamp":1722359604000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/77\/3\/167\/5715227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,24]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,1,24]]},"published-print":{"date-parts":[[2020,1,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxz299","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2,1]]},"published":{"date-parts":[[2020,1,24]]}}}